000 03351nam a22004935i 4500
001 978-3-319-42223-7
003 DE-He213
005 20180206183142.0
007 cr nn 008mamaa
008 160830s2016 gw | s |||| 0|eng d
020 _a9783319422237
_9978-3-319-42223-7
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aDefects in T Cell Trafficking and Resistance to Cancer Immunotherapy
_h[recurso electrónico] /
_cedited by Emmanuel Donnadieu.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2016.
300 _aVIII, 199 p. 27 illus., 19 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v9
505 0 _aIntroduction -- Basic rules of T cell migration -- Regulation of anti-tumor T cell migration and function: contribution of real-time imaging -- Vascular normalization, T cell trafficking and anti-tumor immunity -- Disruption of anti-tumor T cell responses by cancer-associated fibroblasts -- Cancer-associated Tertiary Lymphoid Structures, from basic knowledge toward therapeutic target in clinic -- Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy -- Chemokines and T cell trafficking into tumors. Strategies to enhance recruitment of T cells into tumors -- Strategies to enhance migration and persistence of chimeric antigen receptor (CAR)-T cells into tumors.
520 _aThis volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy. The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aImmunology.
650 0 _aMolecular biology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aImmunology.
650 2 4 _aMolecular Medicine.
700 1 _aDonnadieu, Emmanuel.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783319422213
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v9
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-3-319-42223-7
912 _aZDB-2-SBL
942 _cLIBRO_ELEC
999 _c227954
_d227954